Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG INNOLET versus NOVOLOG MIX 70 30 FLEXPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG INNOLET versus NOVOLOG MIX 70 30 FLEXPEN.
NOVOLOG INNOLET vs NOVOLOG MIX 70/30 FLEXPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It replaces endogenous insulin and has a faster onset and shorter duration than regular human insulin due to altered amino acid sequence (substitution of proline at position 28 with aspartic acid).
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
Subcutaneous injection only. Initial total daily insulin dose: 0.5 to 1 unit/kg/day. Administer 70% intermediate-acting insulin aspart protamine and 30% rapid-acting insulin aspart. Typically given twice daily within 15 minutes before meals. Dose individualize based on glycemic goals.
None Documented
None Documented
Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination
0.5-1 hour for the rapid-acting insulin aspart component and 8-10 hours for the protamine-crystallized insulin aspart component. Clinical context: biphasic profile allows for both prandial and basal coverage.
Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%)
Renal elimination of degradation products. Approximately 30-40% of insulin dose is excreted unchanged in urine; the remainder is metabolized primarily in liver and kidney and excreted as metabolites.
Category C
Category C
Insulin Analog
Insulin Analog